<VariationArchive VariationID="2133196" VariationName="NM_000387.6(SLC25A20):c.645dup (p.Gly216fs)" VariationType="Duplication" Accession="VCV002133196" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2189885" VariationID="2133196">
      <GeneList>
        <Gene Symbol="SLC25A20" FullName="solute carrier family 25 member 20" GeneID="788" HGNC_ID="HGNC:1421" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>3p21.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="48856926" stop="48898882" display_start="48856926" display_stop="48898882" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="48894355" stop="48936425" display_start="48894355" display_stop="48936425" Strand="-" />
          </Location>
          <OMIM>613698</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000387.6(SLC25A20):c.645dup (p.Gly216fs)</Name>
      <CanonicalSPDI>NC_000003.12:48859164:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>3p21.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="48859164" stop="48859165" display_start="48859164" display_stop="48859165" variantLength="1" positionVCF="48859164" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="48896597" stop="48896598" display_start="48896597" display_stop="48896598" variantLength="1" positionVCF="48896597" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
      </Location>
      <ProteinChange>G216fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.48896598dup" Assembly="GRCh37">
            <Expression>NC_000003.11:g.48896598dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.48859165dup" Assembly="GRCh38">
            <Expression>NC_000003.12:g.48859165dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008171.1" sequenceAccession="NG_008171" sequenceVersion="1" change="g.44732dup">
            <Expression>NG_008171.1:g.44732dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000387.6" sequenceAccession="NM_000387" sequenceVersion="6" change="c.645dup" MANESelect="true">
            <Expression>NM_000387.6:c.645dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000378.1" sequenceAccession="NP_000378" sequenceVersion="1" change="p.Gly216fs">
            <Expression>NP_000378.1:p.Gly216fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000387.6(SLC25A20):c.645dup (p.Gly216fs) AND Carnitine acylcarnitine translocase deficiency" Accession="RCV003056225" Version="2">
        <ClassifiedConditionList TraitSetID="3286">
          <ClassifiedCondition DB="MedGen" ID="C0342791">Carnitine acylcarnitine translocase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-03" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-05-03" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">25614308</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3286" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10955" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Carnitine acylcarnitine translocase deficiency</ElementValue>
                <XRef ID="Carnitine-Acylcarnitine+Translocase+Deficiency/1115" DB="Genetic Alliance" />
                <XRef ID="238003000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CACTD</ElementValue>
                <XRef Type="MIM" ID="212138" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Carnitine-acylcarnitine translocase (CACT) is a critical component of the carnitine shuttle, which facilitates the transfer of long-chain fatty acylcarnitines across the inner mitochondrial membrane. CACT deficiency causes a defect in mitochondrial long-chain fatty acid ß-oxidation, with variable clinical severity. Severe neonatal-onset disease is most common, with symptoms evident within two days after birth; attenuated cases may present in the first months of life. Hyperammonemia and cardiac arrhythmia are prominent in early-onset disease, with high rates of cardiac arrest. Other clinical features are typical for disorders of long-chain fatty acid oxidation: poor feeding, lethargy, hypoketotic hypoglycemia, hypotonia, transaminitis, liver dysfunction with hepatomegaly, and rhabdomyolysis. Univentricular or biventricular hypertrophic cardiomyopathy, ranging from mild to severe, may respond to appropriate dietary and medical therapies. Hyperammonemia is difficult to treat and is an important determinant of long-term neurocognitive outcome. Affected individuals with early-onset disease typically experience brain injury at presentation, and have recurrent hyperammonemia leading to developmental delay / intellectual disability. Affected individuals with later-onset disease have milder symptoms and are less likely to experience recurrent hyperammonemia, allowing a better developmental outcome. Prompt treatment of the presenting episode to prevent hypoglycemic, hypoxic, or hyperammonemic brain injury may allow normal growth and development.</Attribute>
                <XRef ID="NBK582032" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1123" />
                <XRef ID="1123" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">35862567</ID>
                <ID Source="BookShelf">NBK582032</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Carnitine-Palmitoyltransferase-2-Deficiency-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased C16 and/or C18:1 Acylcarnitine, Carnitine Palmitoyltransferase II (CPT II) Deficiency and Carnitine Acylcarnitine Translocase (CACT) Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C16 +/- C18:1 Elevated: CPT II or CACT, 2022</CitationText>
              </Citation>
              <XRef ID="159" DB="Orphanet" />
              <XRef ID="C0342791" DB="MedGen" />
              <XRef ID="MONDO:0008918" DB="MONDO" />
              <XRef Type="MIM" ID="212138" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="6042030" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="16544909|MedGen:C0342791" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003346901" DateUpdated="2024-02-20" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">25614308</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This sequence change creates a premature translational stop signal (p.Gly216Trpfs*32) in the SLC25A20 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC25A20 are known to be pathogenic (PMID: 25614308). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SLC25A20-related conditions.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A20" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.48896597_48896598insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0342791" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="6042030" TraitType="Disease" MappingType="XRef" MappingValue="C0342791" MappingRef="MedGen">
        <MedGen CUI="C0342791" Name="Carnitine acylcarnitine translocase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

